CDKN2A/B Mutations and Allele-specific Alterations Stratify Survival Outcomes in IDH-mutant Astrocytomas

Overview

Journal Acta Neuropathol

Specialty Neurology

Date 2023 Oct 13

PMID 37831210

Authors

Richard A Hickman

Erika Gedvilaite

Ryan Ptashkin

Anne S Reiner

Robert Cimera

Subhiksha Nandakumar

Adam Price

Chad Vanderbilt

Tara Fahy

Robert J Young

Alexandra M Miller

Ingo K Mellinghoff

Marc K Rosenblum

Marc Ladanyi

Maria E Arcila

Yanming Zhang

A Rose Brannon

Tejus A Bale

Affiliations

Soon will be listed here.

Citing Articles

Homozygous CDKN2A/B deletions in low- and high-grade glioma: a meta-analysis of individual patient data and predictive values of p16 immunohistochemistry testing.

Noack D, Wach J, Barrantes-Freer A, Nicolay N, Guresir E, Seidel C Acta Neuropathol Commun. 2024; 12(1):180.

PMID: 39593128 PMC: 11590270. DOI: 10.1186/s40478-024-01889-7.

The prognostic impact of CDKN2A/B hemizygous deletions in IDH-mutant glioma.

Ippen F, Hielscher T, Friedel D, Gobel K, Reuss D, Herold-Mende C Neuro Oncol. 2024; 27(3):743-754.

PMID: 39530475 PMC: 11889711. DOI: 10.1093/neuonc/noae238.

Consensus recommendations for an integrated diagnostic approach to peripheral nerve sheath tumors arising in the setting of Neurofibromatosis Type 1.

Lucas C, Gross A, Romo C, Dehner C, Lazar A, Miettinen M Neuro Oncol. 2024; 27(3):616-624.

PMID: 39500722 PMC: 11889724. DOI: 10.1093/neuonc/noae235.

A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design.

Wetzel E, Nohman A, Hsieh A, Reuss D, Unterberg A, Eyupoglu I J Neurooncol. 2024; 171(2):373-381.

PMID: 39432026 PMC: 11695381. DOI: 10.1007/s11060-024-04852-7.

Molecular Profile as an Outcome Predictor in Glioblastoma along with MRI Features and Surgical Resection: A Scoping Review.

Papacocea S, Vrinceanu D, Dumitru M, Manole F, Serboiu C, Papacocea M Int J Mol Sci. 2024; 25(17).

PMID: 39273661 PMC: 11395592. DOI: 10.3390/ijms25179714.

References

Shen R, Seshan V . FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016; 44(16):e131. PMC: 5027494. DOI: 10.1093/nar/gkw520. View

Chakravarty D, Gao J, Phillips S, Kundra R, Zhang H, Wang J . OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol. 2017; 2017. PMC: 5586540. DOI: 10.1200/PO.17.00011. View

Perry A, Anderl K, Borell T, Kimmel D, Wang C, OFallon J . Detection of p16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas. Am J Clin Pathol. 1999; 112(6):801-9. DOI: 10.1093/ajcp/112.6.801. View

Zehir A, Benayed R, Shah R, Syed A, Middha S, Kim H . Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017; 23(6):703-713. PMC: 5461196. DOI: 10.1038/nm.4333. View

Kocakavuk E, Johnson K, Sabedot T, Reinhardt H, Noushmehr H, Verhaak R . Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas. Neuro Oncol. 2023; 25(9):1721-1723. PMC: 10479907. DOI: 10.1093/neuonc/noad095. View